Acteryonsp. z o.o.
Other research and experimental development on natural sciences and engineering
Overview
Acteryon is a biotechnology company researching and developing therapies and technologies based on bacteriophages. It provides end-to-end development, from phage isolation and characterization to formulation and production of cGMP batches for clinical trials, under GLP and GMP standards.
Financials
Revenue history (in k)
Financial insight
- Possible Estonian CIT: Equity includes Art. 28d line items, but all amounts are 0 – this may be an accounting template or the first year of the regime.
Filing timeliness
1 of 6 financial statements was filed late (for 2021, 62 days late).
- 202519/05/2026
- 202428/05/2025
- 202303/06/2024
- 202228/06/2023
- 202115/09/2022
- 202029/09/2021
Data and insights are generated automatically from financial statements – they may contain errors and are neither a credit assessment nor business advice.
Statistics
How the company ranks by revenue within its industry, region and across Poland in 2025.
Results vs industry
Industry
Offer
- Biological research
- Research and development
- Dermocosmetic ingredient
- Bacteriophage nanoparticles
- Anti-acne product
Website technology
- Online shop
- WooCommerce
- Website
- WordPress
- Elementor
- Analytics and marketing
- Google Analytics
Authorized Representatives
Manner of representation
Each member of the management board is authorized to make declarations on behalf of the company independently.
Ownership
| Owner | Shares | Share value | Stake |
|---|---|---|---|
Piotr Wojciech Gierszewskiage 53 | 78,250 | $2,113,722.31 | 85.0543% |
Marcin Przemysław Łośage 50 | 13,750 | $371,420.85 | 14.9457% |
Beneficial owners
| Person | Rights |
|---|---|
Bank accounts
Registered as a VAT taxpayer on 2017-12-01.
Debt
No entries in the National Debtors Register (KRZ).
Real estate
| Type | Amount |
|---|---|
Land (incl. perpetual usufruct) | $355.5K$355,519 |
Buildings and premises | $3.7M$3,689,973 |
Public aid
24 public aid cases recorded, with a total value of $5,441,381.
| Grant date | Purpose | Gross amount | Granting body | |
|---|---|---|---|---|
| Oct 22, 2025 | De minimis aid (in accordance with Commission Regulation 2023/2831) | $904$904 | Agencja Rozwoju Pomorza S.A. | |
| Nov 3, 2023 | De minimis aid (in accordance with Commission Regulation No 1407/2013 or earlier) | $5,399$5,399 | Prezydent Miasta Gdynia | |
| Nov 3, 2023 | De minimis aid (in accordance with Commission Regulation No 1407/2013 or earlier) | $3$3 | Prezydent Miasta Gdynia |
European Funds
5 projects co-financed from European Funds recorded, with total EU co-financing of $7,010,957.
| Start | Project | EU co-financing | Programme | |
|---|---|---|---|---|
| 2025-06-01 | Endobiotyk – an innovative biopreparation for special medical purposes, intended for patients with small intestinal bacterial overgrowth (SIBO) | $1.1M$1,124,869 | European Funds for Pomerania 2021-2027 | |
| 2021-07-01 | Next-generation dermocosmetic based on bionanoparticles active against Propionibacterium acnes. | $892.4K$892,436 | Operational Programme Smart Growth | |
| 2021-06-01 | Phage endolysin with a broad spectrum of antibacterial activity as a modern food additive preventing infections caused by L. monocytogenes strains. | $793.1K$793,149 | Operational Programme Smart Growth |
Regulatory authorisations
| Authority | Type | Status | |
|---|---|---|---|
 BDO | BDO register entry | Active |
Competitors
| Name | Revenue | Website | ||
|---|---|---|---|---|
| Medicofarma BiotechS.A. | $314,882.33 | medicofarmabiotech.pl | ||
| FcbiotechS.A. | $246,877.92 | fcbiotech.pl | ||
| Genelyticasp. z o.o. | $213,207.91 | genelytica.pl | ||
| TCIsp. z o.o. | $218,471.87 | tci.pl | ||
| Bactremsp. z o.o. | $181,958.36 | bactrem.pl | ||
| Countess Laboratoriessp. z o.o. | $164,970.29 | countess.pl | ||
| SN Biotech Technologiessp. z o.o. + limited partnership | $144,861.78 | snbiotech.com | ||
| Bioaidsp. z o.o. | $94,146.77 | bioaid.pl | ||
| Sfpesp. z o.o. | $72,850.26 | sfpe.co.pl | ||
| Receptonsp. z o.o. | $50,611.05 | receptonbiotech.com |
Change history
| Date | Event | |
|---|---|---|
| 2024-06-06 | Share capital increase (4,200,000.00 PLN → 9,200,000.00 PLN) | |
| 2024-02-08 | Address change (Al. Zwycięstwa 96/98/254, 81-451, Gdynia → Ul. Geodetów 19b, 80-298, Gdańsk) | |
| 2023-10-18 | Address change (Al. Zwycięstwa 96/98/257, 81-451, Gdynia → Al. Zwycięstwa 96/98/254, 81-451, Gdynia) | |
| 2023-08-04 | Share capital increase (1,950,000.00 PLN → 4,200,000.00 PLN) | |
| 2023-06-06 | Share capital increase (450,000.00 PLN → 1,950,000.00 PLN) |
FAQ
Last updated: 2026-05-19